Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / GP73

GP73

Basics

Aliases:
This biomarker is also known as:
  • chromosome 9 open reading frame 155,
  • golgi membrane protein 1,
  • FLJ23608,
  • GOLPH2,
  • bA379P1.3,
  • FLJ22634,
  • PSEC0257,
  • C9orf155,
  • GOLM1,
  • golgi phosphoprotein 2,

View in BioMuta

Description…

The Golgi complex plays a key role in the sorting and modification of proteins exported from the endoplasmic reticulum. GP73 is a type II Golgi transmembrane protein. It processes proteins synthesized in the rough endoplasmic reticulum and assists in the transport of protein cargo through the Golgi apparatus. The expression of the GP73 gene has been observed to be upregulated in response to viral infection. Alternatively spliced transcript variants encoding the same protein have been described for this gene. Kladeny, RD. et al. 2000, found significant up-regulation of GOLPH2 expression in human hepatocyte cells infected with a recombinant adenovirus. EDRN investigator Block, TM et al. 2005, found that GP73 over-expression in serum correlate with liver cancer in woodchucks and humans. Chinnayian's lab reported that GP73 transcript was over-expressed in prostate cancer patients urine sediment (Laxman B. et al. 2008).

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: GOLM1

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Liver

Attributes

Phase: Two
QA State: Under Review

Overview

Golgi protein-73 (GP73) is up-regulated in hepatocellular carcinoma (HCC).

Performance Comment

GP73 is used together with AFP-L3 in China for monitoring/risk assessment of cirrhotic patients for hepatocellular carcinoma (HCC).

Prostate

Attributes

Phase: Two
QA State: Under Review

Overview

GOLPH2 protein is highly expressed in seminomas and in Leydig cell tumours.

Performance Comment

Increased GOLPH2 (GP73) transcript expression can be a predictor of prostate cancer. A multiplexed model including seven biomarkers (AMACR, ERG, GOLPH2, PCA3, SPINK1, TFF3, TMPRSS2:ERG) outperforms serum PSA or PCA3 alone.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.